Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating expenses:    
Research and development $ 2,406 $ 1,349
General and administrative 1,213 1,055
Operating loss (3,619) (2,404)
Other (income) expense:    
Governmental assistance - research incentives (115)
Other (income) expense, net (4) 127
Total other (income) expense (4) 12
Loss before income tax expense (3,615) (2,416)
Income tax expense 7 9
Net loss (3,622) (2,425)
Other comprehensive income (loss)    
Unrealized gain (loss) on marketable securities (2) 40
Net loss and comprehensive loss $ (3,624) $ (2,385)
Basic and diluted net loss per share (in dollars per share) $ (0.19) $ (0.19)
Weighted average shares outstanding – basic and diluted (in shares) 18,766,656 13,107,725